New Delhi, Nov 12 (PTI) A sector-wise assessment of PLI scheme shows that nearly 70 per cent of the targeted segments are on track, with particularly strong outcomes emerging in electronics, telecom and pharmaceuticals drugs, NITI Aayog said in a report on Thursday.
As of March 2026, cumulatively the scheme has attracted investments of Rs 2,40,138 crore, generated production worth Rs 22,66,412 crore, created employment for 8,49,069 individuals, and disbursed Rs 35,354 crore in incentives.
“The assessment indicates that the production linked incentive (PLI) scheme is beginning to generate meaningful additionality across several sectors.
“…the sector-wise assessment of PLI scheme indicates that nearly 70 per cent of the targeted segments are broadly on track, with particularly strong outcomes emerging in electronics, telecom and pharmaceuticals drugs,” the report ‘Impact Assessment of PLI Schemes’ said.
The report pointed out that large scale electronics manufacturing (LSEM) with an outlay of Rs 34,193 crore has emerged as one of the strongest performers, particularly in mobile manufacturing, with significant growth in production, sales, exports and employment across both domestic and global firms.
The PLI scheme is a major policy initiative of the government aimed at strengthening domestic manufacturing, attracting investment, creating employment, promoting exports and building globally competitive production capabilities.
It has been introduced across 14 sectors to realise India’s vision of becoming a manufacturing hub and has a combined financial outlay of Rs 1,91,049 crore, against which cumulative disbursements stood at Rs 35,354 crore as of March 2026, representing 18.51 per cent of the total outlay.
The report said at the same time, the pace of outcomes varies across sectors, reflecting differences in the maturity of the schemes, investment cycles and sectoral characteristics.
“These aggregate outcomes provide the broader context for examining the financial architecture of the PLI framework and the extent to which the allocated resources have translated into actual disbursements,” it said.
According to the report, sectors including automobiles and auto components, telecom and speciality steel, demonstrate encouraging progress, particularly in investment and production, but require further strengthening in areas such as employment, exports and domestic value addition.
“In relatively newer or more capital-intensive sectors such as ACC batteries and advanced electronic components, outcomes remain at an early stage,with substantial investments still in the capacity-creation and commissioning phase,” the Aayog said.
LSEM with an outlay of Rs 34,193 crore has emerged as one of the strongest performers, particularly in mobile manufacturing, with significant growth in production, sales, exports and employment across both domestic and global firms.
“The scheme has successfully expanded production, attracted investment, and generated employment, while also laying the foundation for the recently launched Electronics Component Manufacturing Scheme (ECMS) with an outlay of Rs 40,000 crore,” it said.
Overall, the Aayog said LSEM scheme shows strong progress, particularly in mobile manufacturing.
Releasing the report, NITI Aayog Vice Chairman Ashok Kumar Lahiri said manufacturing has long been recognised as an engine of employment, innovation and productivity-led growth.
“For India, as it advances towards the vision of Viksit Bharat @2047, strengthening manufacturing capabilities will be central to sustaining high, inclusive and broad-based growth,”Lahiri said.
NITI Aayog CEO Anurag Jain said real manufacturing GVA increased from Rs 34.82 lakh crore in FY 2022–23 to Rs 47.47 lakh crore in FY 2025–26, registering a CAGR of 10.88 per cent and cumulative growth of 36.3 per cent over the period.
“Sustaining this momentum is essential for strengthening India’s manufacturing sector,” Jain added.
According to the report, the Pharma Bulk Drugs scheme with an outlay of Rs 6,940 crore presents a more differentiated picture across its four target segments.
The Aayog said the Pharmaceuticals Drugs PLI scheme with an outlay of Rs 15,000 crore demonstrates broadly positive outcomes across all four parameters.
“Large firms have recorded the strongest performance, supported by scale and integration with global markets, while mid-sized firms have shown steady improvement,” it said.
While MSMEs have experienced more uneven outcomes, particularly in exports, reflecting constraints relating to scale and market access, the report said investment has consistently exceeded targets, while production and employment have recorded significant growth, indicating a positive overall industrial impact from the scheme.
The Aayog said Automobile and Auto Components PLI scheme, with an outlay of Rs 25,938 crore, has generated substantial investment, with Rs 44,326 crore invested by March 2026.
According to the Aayog, the Drones and Drone Components scheme, with an outlay of only Rs 120 crore, has demonstrated strong early momentum.
“By the period covered in the assessment, 77.5 per cent of the allocated funds had been disbursed, with most approved firms receiving incentives,”it said. PTI BKS BKS ANU
ANU
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.